scholarly journals Targeting ATR and Chk1 kinases for cancer treatment: A new model for new (and old) drugs

2011 ◽  
Vol 5 (4) ◽  
pp. 368-373 ◽  
Author(s):  
Luis I. Toledo ◽  
Matilde Murga ◽  
Oscar Fernandez-Capetillo
Keyword(s):  
2020 ◽  
Vol 19 (3) ◽  
pp. 365-371
Author(s):  
S Sindhu ◽  
S Murugan

for treating a new clinical condition takes time and consumes a lot of investment. Therefore, there is much attention given towards repurposing of old drugs for new therapy. Majority of drugs approved by FDA for a particular treatment has found applications in the treatment of various other clinical conditions too. In other words, it can be said as ‘reusing’ of a drug. This mini review focused on the use of repurposed drugs for bacterial infections and cancer treatment. Apart from the benefits of repurposing of drugs, there are some challenges needed to be addressed. Therefore, in this review paper the use of repurposed drugs in treatment of communicable (bacterial infections) and non-communicable (cancer) diseases were discussed. Bangladesh Journal of Medical Science Vol.19(3) 2020 p.365-371


2016 ◽  
Vol 34 (3_suppl) ◽  
pp. 46-46
Author(s):  
Kristina M Diaz ◽  
Edward Paul ◽  
Gregory John C. Yang ◽  
Shirley Phillips ◽  
John Bowles ◽  
...  

46 Background: The active role of a primary care physician has been shown to improve outcomes for patients in all areas of health management. Cancer care is rapidly evolving as a result of major advances in cancer genomics and the production of new, mostly oral, chemotherapeutic agents targeted to specific patients. The estimated number of cancer survivors is expected to dramatically increase in the next decade. One good example of a new model of cancer care that relies upon the steady presence and involvement of the primary care physician is the care of patients with non-metastatic breast cancer. The current model of breast cancer care includes the primary physician identifying a lesion, obtaining required imaging, making a preliminary diagnosis of presumptive breast cancer, referring to the surgeon and/or oncologist, then resuming care of the patient post survivorship. In the new model of care described here, oncologists play a peripheral role and once therapy is initiated, care by the primary care physician in an integrated, team-oriented, system becomes ideal. Methods: Via a shared care model in which the primary physician is trained to provide direct oncologic care for the patient. They will thereafter initiate a survivor plan that will allow the patient to return to their own medical ecosystem with the least delay and compromise. The primary physician is anticipated to actively direct care for the cancer patient including prescribing recommended cancer treatment, managing medication side effects, and making appropriate referrals when necessary. Results: see below Conclusions: There is good evidence that outcomes by a primary care physician throughout the entire breast cancer treatment phase are comparable to care provided by oncologists in the current model. When the primary care physician is given the right tools and empowered to lead the care for the patient, improved compliance, improved psychosocial quality, and appropriate survivorship follow up can be achieved. With the ability to care for all aspects of their patient’s needs, both biomedical and emotional, the primary physician can, and should, start taking a more active and holistic role in providing care for their patients. Never was this more true then now.


Pharmaceutics ◽  
2020 ◽  
Vol 12 (5) ◽  
pp. 410 ◽  
Author(s):  
Filipa Moreira-Silva ◽  
Vânia Camilo ◽  
Vítor Gaspar ◽  
João F. Mano ◽  
Rui Henrique ◽  
...  

Epigenetic alterations, as a cancer hallmark, are associated with cancer initiation, progression and aggressiveness. Considering, however, that these alterations are reversible, drugs that target epigenetic machinery may have an inhibitory effect upon cancer treatment. The traditional drug discovery pathway is time-consuming and expensive, and thus, new and more effective strategies are required. Drug Repurposing (DR) comprises the discovery of a new medical indication for a drug that is approved for another indication, which has been recalled, that was not accepted or failed to prove efficacy. DR presents several advantages, mainly reduced resources, absence of the initial target discovery process and the reduced time necessary for the drug to be commercially available. There are numerous old drugs that are under study as repurposed epigenetic inhibitors which have demonstrated promising results in in vitro tumor models. Herein, we summarize the DR process and explore several repurposed drugs with different epigenetic targets that constitute promising candidates for cancer treatment, highlighting their mechanisms of action.


2021 ◽  
pp. 109952
Author(s):  
José T. Silva ◽  
Carla Daruich de Souza ◽  
Lucas Verdi Angelocci ◽  
Wilmmer Alexander Arcos Rosero ◽  
Beatriz Ribeiro Nogueira ◽  
...  

Author(s):  
H. Akabori ◽  
K. Nishiwaki ◽  
K. Yoneta

By improving the predecessor Model HS- 7 electron microscope for the purpose of easier operation, we have recently completed new Model HS-8 electron microscope featuring higher performance and ease of operation.


2005 ◽  
Vol 173 (4S) ◽  
pp. 140-141
Author(s):  
Mariana Lima ◽  
Celso D. Ramos ◽  
Sérgio Q. Brunetto ◽  
Marcelo Lopes de Lima ◽  
Carla R.M. Sansana ◽  
...  

2004 ◽  
Vol 171 (4S) ◽  
pp. 284-284
Author(s):  
Yi Lu ◽  
Jun Zhang ◽  
Ben Beheshti ◽  
Ximing J. Yang ◽  
Syamal K. Bhattacharya ◽  
...  

2009 ◽  
Vol 43 (6) ◽  
pp. 30
Author(s):  
GREG FEERO
Keyword(s):  

Sign in / Sign up

Export Citation Format

Share Document